Skip to main content
Canadian Family Physician logoLink to Canadian Family Physician
. 1989 Oct;35:2123–2125.

New Perspectives in Multiple Sclerosis

D W Paty
PMCID: PMC2280928  PMID: 21249093

Abstract

Multiple sclerosis, a potentially disabling disease of young adults, is caused by as yet unknown agents. Recent studies suggest a genetic susceptibility factor with a superimposed environmental triggering or causative agent. New methods of diagnosing and monitoring multiple sclerosis, such as magnetic resonance imaging, are providing new insights into pathogenesis. Important new classes of drugs on the horizon may well help to retard the disease process.

Keywords: degenerative diseases, multiple sclerosis, neurology

Full text

PDF
2123

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bauer H. J. Multiple sclerosis in Europe. J Neurol. 1987 May;234(4):195–206. doi: 10.1007/BF00618250. [DOI] [PubMed] [Google Scholar]
  2. Ebers G. C., Bulman D. E., Sadovnick A. D., Paty D. W., Warren S., Hader W., Murray T. J., Seland T. P., Duquette P., Grey T. A population-based study of multiple sclerosis in twins. N Engl J Med. 1986 Dec 25;315(26):1638–1642. doi: 10.1056/NEJM198612253152603. [DOI] [PubMed] [Google Scholar]
  3. Kurtzke J. F., Hyllested K. Multiple sclerosis in the Faroe Islands. III. An alternative assessment of the three epidemics. Acta Neurol Scand. 1987 Nov;76(5):317–339. doi: 10.1111/j.1600-0404.1987.tb03590.x. [DOI] [PubMed] [Google Scholar]
  4. McDonald W. I. The role of NMR imaging in the assessment of multiple sclerosis. Clin Neurol Neurosurg. 1988;90(1):3–9. doi: 10.1016/s0303-8467(88)80002-7. [DOI] [PubMed] [Google Scholar]
  5. Morel E., Eymard B., Vernet-der Garabedian B., Pannier C., Dulac O., Bach J. F. Neonatal myasthenia gravis: a new clinical and immunologic appraisal on 30 cases. Neurology. 1988 Jan;38(1):138–142. doi: 10.1212/wnl.38.1.138. [DOI] [PubMed] [Google Scholar]
  6. Paty D. W. Magnetic resonance imaging in the assessment of disease activity in multiple sclerosis. Can J Neurol Sci. 1988 Aug;15(3):266–272. doi: 10.1017/s0317167100027724. [DOI] [PubMed] [Google Scholar]
  7. Paty D. W., Oger J. J., Kastrukoff L. F., Hashimoto S. A., Hooge J. P., Eisen A. A., Eisen K. A., Purves S. J., Low M. D., Brandejs V. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology. 1988 Feb;38(2):180–185. doi: 10.1212/wnl.38.2.180. [DOI] [PubMed] [Google Scholar]
  8. SCHUMACHER G. A., BEEBE G., KIBLER R. F., KURLAND L. T., KURTZKE J. F., MCDOWELL F., NAGLER B., SIBLEY W. A., TOURTELLOTTE W. W., WILLMON T. L. PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS. Ann N Y Acad Sci. 1965 Mar 31;122:552–568. doi: 10.1111/j.1749-6632.1965.tb20235.x. [DOI] [PubMed] [Google Scholar]
  9. Sadovnick A. D., Macleod P. M. The familial nature of multiple sclerosis: empiric recurrence risks for first, second-, and third-degree relatives of patients. Neurology. 1981 Aug;31(8):1039–1041. doi: 10.1212/wnl.31.8.1039. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Family Physician are provided here courtesy of College of Family Physicians of Canada

RESOURCES